SCHEMBL282279

SCHEMBL282279

CCOP(=O)(COS(=O)(=O)C(F)(F)F)OCC

nearest known ligand 0.41

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.41
PPARD Q03181 1/20 0.36
TP53 P04637 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
CA2 P00918 1/20 0.31
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13850203 0.85 MEN1 (0.33) CA2
SCHEMBL13654619 0.84 TSHR (0.41) TSHRCA2ALDH1A1
SCHEMBL12150262 0.83 TSHR (0.33) TSHRTP53TDP1CA2
SCHEMBL13541197 0.82 CYP3A4 (0.42) TSHRCA2
SCHEMBL13537808 0.82 GAA (0.34) TP53ALDH1A1
SCHEMBL5791990 0.81 PPARD (0.42) TSHRPPARDTP53TDP1CA2
SCHEMBL14108412 0.81 PPARD (0.41) TSHRPPARDTP53TDP1
SCHEMBL281841 0.80 TSHR (0.52) TSHRPPARD
SCHEMBL3380154 0.80 CA2 (0.33) CA2
SCHEMBL16199351 0.79 CA2 (0.33) CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250319113-A1 INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE ARCUS BIOSCIENCES INC (US) 2025-10-16 US disclosed
US-12421273-B2 Ectonucleotidase inhibitors and methods of use thereof ANTENGENE THERAPEUTICS LIMITED (CN) 2025-09-23 US disclosed
US-12168023-B2 Inhibitors of adenosine 5′-nucleotidase ARCUS BIOSCIENCES, INC. (US) 2024-12-17 US disclosed
US-20240285665-A1 INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE ARCUS BIOSCIENCES, INC. 2024-08-29 US disclosed
US-12037586-B2 4′-phosphate analogs and oligonucleotides comprising the same DICERNA PHARMACEUTICALS, INC. (US) 2024-07-16 US disclosed
WO-2024107859-A1 CYCLOPENTENE-OXYMETHYLENE PHOSPHONAMIDATES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS ROME THERAPEUTICS, INC. (US) 2024-05-23 WO disclosed
US-20240132533-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF ANTENGENT THERAPEUTICS LIMITED (CN) 2024-04-25 US disclosed
US-11858957-B2 Ectonucleotidase inhibitors and methods of use thereof ANTENGENT THERAPEUTICS LIMITED (CN) 2024-01-02 US disclosed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 US disclosed
US-20230212203-A1 Antiviral Compounds UNIVERSITY OF MASSACHUSETTS 2023-07-06 US disclosed
WO-1996037494-A1 BICYCLIC AMINES AS INSECTICIDES ZENECA LIMITED (GB) 1996-11-28 WO disclosed
EP-0269947-B2 Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives ACAD OF SCIENCE CZECH REPUBLIC (CS) 1996-10-16 EP disclosed
WO-1996023813-A1 PEPTIDES AND COMPOUNDS THAT BIND TO SH2 DOMAINS AFFYMAX TECHNOLOGIES N.V. (AN) 1996-08-08 WO disclosed
EP-0369409-B1 Carbocyclic nucleosides and nucleotides ACAD OF SCIENCE CZECH REPUBLIC (CS) 1995-01-04 EP disclosed
US-5246931-A Triazine-substituted cyclobutane derivatives; viricides; side effect reduction BRISTOL-MYERS SQUIBB COMPANY (US) 1993-09-21 US disclosed
US-5153352-A Viricides and antitumor agent BRISTOL-MYERS SQUIBB COMPANY (US) 1992-10-06 US disclosed
EP-0485026-A2 Antimanic phenoxymethylene bisphosphonate derivatives MERCK SHARP & DOHME LTD. (GB) 1992-05-13 EP disclosed
EP-0369409-A1 Carbocyclic nucleosides and nucleotides INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) 1990-05-23 EP disclosed
EP-0366059-A2 Carbocyclic nucleoside analogs BRISTOL-MYERS SQUIBB COMPANY (US) 1990-05-02 EP disclosed
EP-0269947-A1 Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) 1988-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132533-A1 ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF NT5E, ENTPD5, NT5C2 TSHR 2756/4885PPARD 3300/4885TP53 2516/4885
US-11802135-B2 Lysophosphatidic acid derivative LPAR4, LPAR2, LPAR1 TSHR 1842/4885PPARD 159/4885TP53 3899/4885
US-20250319113-A1 INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE ENTPD5, NT5C2, ENTPD1 TSHR 3077/4885PPARD 3424/4885TP53 1173/4885
US-11858957-B2 Ectonucleotidase inhibitors and methods of use thereof NT5E, ENTPD5, NT5C2 TSHR 2756/4885PPARD 3300/4885TP53 2516/4885
US-12168023-B2 Inhibitors of adenosine 5′-nucleotidase ENTPD5, NT5C2, ENTPD1 TSHR 3063/4885PPARD 3424/4885TP53 1160/4885
US-12421273-B2 Ectonucleotidase inhibitors and methods of use thereof NT5E, ENTPD5, NT5C2 TSHR 2756/4885PPARD 3300/4885TP53 2516/4885
US-12037586-B2 4′-phosphate analogs and oligonucleotides comprising the same RNGTT, DERA, MTAP TSHR 3081/4885PPARD 4062/4885TP53 656/4885
US-20230212203-A1 Antiviral Compounds ZC3HAV1, EIF2AK2, MAVS TSHR 4819/4885PPARD 3533/4885TP53 2100/4885
US-20240285665-A1 INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE ENTPD5, NT5C2, ENTPD1 TSHR 3077/4885PPARD 3424/4885TP53 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.